AGENDA DAY 3

 

Day 3 Oct 12th Immune Profiling

09:00

Chair’s opening remarks

IMMUNE RESPONSE AND BIOMARKERS: B-CELL & T-CELL ANALYSIS

Dr Christian Brander
09:10

Immune correlates and biomarkers of HIV control after therapeutic HIV vaccination and treatment interruption

Dr Christian Brander, CSO Aelix Therapeutics, ICREA Research Professor, IrsiCaixa A.I.D.S. Research Institute
Yariv Wine
09:40

Immune profiling of anti-drug antibodies

Dr David Krige
10:10

Developing effective biomarker strategies for advanced clinical development of Immune mobilising monoclonal TCRs against cancer (ImmTACs)

 
  • Sharing updates on the phase I/IIa clinical trials in advanced melanoma
  • Employing a unique biomarker strategy which allows for comprehensive analysis of markers within the tumour as well as the surroundings
  • Enhanced knowledge acquired regarding the biologic mechanisms and response rates
10:40

Networking Break

Dr Laura Rosa Brunet
11:20

Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments

  • The potential to develop drugs from bugs
  • The Old Friend’s hypothesis: implications for the field of immunotherapy
  • Overview of current clinical and pre-clinical development programmes
  • Highlighting immune-modulatory mode of mechanism

IMMUNO-ONCOLOGY, CHRONIC & AUTOIMMUNE DISEASE APPROACHES

Dr Sandrine Crabe
11:50

ABX196, a promising iNKT agonist to enhance therapeutic efficacy in oncology


 
12:20

Networking Lunch

Dr Rachel Abbott
13:20

Engineering 2nd Generation SPEAR™-T cells to Overcome TGF-β-Mediated Immunosuppression

 
  • NY-ESO SPEAR-T cells show promise in clinical trials for solid and liquid tumours
  • Depth and durability of responses may be affected by inhibitory cytokines such as Transforming Growth Factor-β (TGF-β) in the tumour microenvironment
  • Preclinical assessment of a dominant negative TGF-β receptor (dnTGFβRII) to make T cells resistant to the inhibitory effects of TGF-β
Dr Philip Arlen
13:50

Targeting cancer neoantigens: a promising source of immunogens for cancer immunotherapy

 
  • Employing novel antibodies against immunogenic neoantigens
  • Antibody development using a novel platform exploiting immunogenic human tumor antigens
  • How to identify tumor specific monoclonal antibodies with anti-tumor activity and target antigens
  • Sharing pre-clinical and PhII clinical data in patients  
Reece Marillier
14:20

Enabling boosted anti-tumor immunity by use of an immuno-oncology-dedicated adenosine receptor antagonist

 
  • Sharing data updates
  • Characterization of a novel Adenosine A2A Receptor antagonist optimized to function in high adenosine concentrations within tumors
  • Defining the receptors essential for mediation of the effect of adenosine on immune cells within the tumor microenvionment
  • Translational strategy to improve the antitumor efficacy in patients
Dr Tanja De Gruijl
14:50

  Immunoprofiling of tumour-draining lymph nodes: new targets for early intervention

 
  • Immunoprofiling of lymph nodes draining various tumor types has uncovered different immune suppressive mechanisms at play  
  • Different combinations of locally applied TLR-ligands and/or immune checkpoint inhibitors should be considered for therapeutic conditioning of lymph nodes draining different tumor types.
  • Immune suppression of migratory and resident DC subsets in melanoma sentinel lymph nodes is differentially related to locoregional and distant metastasis.
  • Local immune modulation of melanoma-draining lymph nodes by CpG or anti-CTLA4 leads to systemic T cell immunity and protection against metastatic spread.
15:20

Chair’s closing remarks and close of Congress

last published: 06/Oct/17 08:25 GMT